Health Technology · Pharmaceuticals: Major · NSE: LINCOLN · data 2026-10-09

Lincoln Pharmaceuticals Ltd

Health check: Strong (7/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹558.3

Market cap

₹1,123 cr

P/E

11.6

P/B

—

ROE

12.3%

ROCE

10.9%

Debt / equity

0.01

Dividend yield

0.32%

1-year return

5.7%

52-week high

₹770

52-week low

₹440

Operating margin

12.4%

Growth

Revenue (last 12 months)	₹694 cr
Net profit (last 12 months)	₹96 cr
Sales growth, 3 years (yearly)	9.4%
Profit growth, 3 years (yearly)	6.4%

Similar companies

Kopran Limited (KOPRAN) · Remus Pharmaceuticals Ltd. (REMUS) · Sigachi Industries Limited (SIGACHI) · Bajaj Healthcare Ltd (BAJAJHCARE) · Themis Medicare Limited (THEMISMED)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open LINCOLN in NSE Scanner →